ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Fabrication of epidermal growth factor (EGF)- and vancomycin-loaded chitosan nanoparticles to enhance wound healing.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Novel Nanoantibiotic Formulation With Magnetic and Targeting Potential: Ampicillin-Conjugated L-glu-FeMicrobiologyOpen · 2026Article
- Development and Optimization of 7,8-Dihydroxyflavone-Loaded Polylysine/Lecithin Nanoparticles for Potential Intranasal Delivery.Pharmaceutics · 2026Article
- Advances in Nanotechnology-Assisted Delivery of TCM-Derived Bioactive Compounds for Wound Repair.Pharmaceutics · 2026Review
- Adipose Tissue Engineering Biomaterials: Smart Scaffolds, Vascularization, and Clinical Frontiers.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delayed and impaired wound healing is a persistent issue, these wounds are prone to infections and suffer from poor cell re-epithelization. Nanoparticles can be utilized to aid in the wound healing process, they are able to carry and deliver biomolecules and drugs into wounds. Due to their small sizes, they can deeply penetrate tissues. This study reports the development of a dual-delivery system of chitosan nanoparticles (CSNPs) co-encapsulating epidermal growth factor (EGF) and vancomycin (VCM) for potential application in wound healing. The nanoparticles were fabricated using the ionotropic gelation method with tripolyphosphate anions (TPP) and characterized for their physicochemical properties including the size, shape, polydispersity index, and zeta potential of the nanoparticles. High-performance liquid chromatography (HPLC) was utilized to measure the encapsulation efficiency of the nanoparticles and to evaluate the release kinetics. The dual-loaded CSNPs exhibited a mean particle size of 458.39 nm and a high positive zeta potential. The encapsulation efficiency and in vitro release kinetics were quantified by HPLC. The formulation demonstrated a sustained release profile for both EGF and VCM. The nanoparticles showed no significant cytotoxicity against human dermal fibroblasts (HDFs) at concentrations up to 4 mg/ml and exhibited a minimum inhibitory concentration (MIC) of 2 mg/ml against Staphylococcus aureus. Furthermore, the dual-loaded nanoparticles significantly enhanced cell migration in an in vitro scratch assay, indicating their potential to accelerate wound closure. This work highlights the promise of dual-loaded chitosan nanoparticles as a novel therapeutic strategy to simultaneously promote tissue regeneration and combat bacterial infections in wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.